Details for Patent: 10,357,468
✉ Email this page to a colleague
Which drugs does patent 10,357,468 protect, and when does it expire?
Patent 10,357,468 protects ONGENTYS and is included in one NDA.
This patent has nine patent family members in seven countries.
Summary for Patent: 10,357,468
Title: | Medicaments for slowing Parkinson's disease |
Abstract: | Opicapone, levodopa and an AADC inhibitor are described for use in slowing the progression of Parkinson's Disease. |
Inventor(s): | Soares da Silva; Patricio Manuel Vieira Araujo (Sao Mamede do Coronado, PT), Rocha; Jose Francisco da Costa de Pinho (Sao Mamede do Coronado, PT) |
Assignee: | BIAL--PORTELA & CA, S.A. (Sao Mamede do Coronado, PT) |
Application Number: | 15/528,886 |
Patent Claim Types: see list of patent claims | Use; Dosage form; |
Recent additions to Drugs Protected by US Patent 10,357,468
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurocrine | ONGENTYS | opicapone | CAPSULE | 212489 | Apr 24, 2020 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-2812 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,357,468
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-001 | Apr 24, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-002 | Apr 24, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,357,468
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
PCT/IB2014/003241 | Nov 28, 2014 |
PCT Information | |||
PCT Filed | May 27, 2015 | PCT Application Number: | PCT/IB2015/000766 |
PCT Publication Date: | June 02, 2016 | PCT Publication Number: | WO2016/083875 |
International Family Members for US Patent 10,357,468
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2015352158 | ⤷ Try a Trial | |||
Brazil | 112017011168 | ⤷ Try a Trial | |||
Japan | 2018500300 | ⤷ Try a Trial | |||
South Korea | 20170090458 | ⤷ Try a Trial | |||
Mexico | 2017006953 | ⤷ Try a Trial | |||
Mexico | 2021010886 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |